ETX2514 Publications and Presentations

Our scientific publications in high-quality journals reflect the quality of the innovative research in Entasis’ laboratories.

S. McLeod, A. Shapiro, S. Moussa, M. Johnstone, R. McLaughlin, B. de Jonge and A. Miller
Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii
Antimicrob. Agents Chemother. February 2018 vol. 62 no. 2 e01576-17

Presentation Title: Discovery of ETX2514, a novel, rationally designed inhibitor of Class A, C and D B-lactamases, for the treatment of Gram-negative infections
Presented by: Thomas Durand-Reville
Meeting: ACS Meeting, 2017

Presentation Title: Pathogen-directed strategies at Entasis Therapeutics
Presented by: Alita Miller
Meeting: SDRI, 2017

Poster Title:  Reversibility of b-lactamase inhibition by the broad-spectrum diazabicyclooctenone serine b-lactamase inhibitor ETX2514
Presented by:  Adam Shapiro
Meeting:  ASM Microbe, New Orleans, June 2017

Poster Title:  The Antibacterial Activity of Sulbactam and the Novel b-lactamase Inhibitor ETX2514 Combined with Imipenem or Meropenem Against Recent Clinical Isolates of Acinetobacter baumannii and Pseudomonas aeruginosa

Presented by:  Sarah McLeod
Meeting:  ASM Microbe, New Orleans, June 2017

Presentation Title:  ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens
Presented by:  Ruben Tommasi
Meeting:  ECCMID, Vienna, April 2017

Presentation Title:  ETX2514 restoration of sulbactam activity against multidrug resistant Acinetobacter baumannii correlates with β-lactamase inhibition in vitro and in vivo
Presented by:  Alita Miller
Meeting:  ECCMID, Vienna, April 2017

J. Lickliter, K. Lawrence, J. O’Donnell, and R. Isaacs
Safety and Pharmacokinetics (PK) in Humans of Intravenous ETX2514, a β-lactamase Inhibitor (BLI) which Broadly Inhibits Ambler Class A, C, and D β-lactamases
IDWeek 2017 conference in San Diego (2017)

Adam B. Shapiro, Ning Gao, Haris Jahić, Nicole M. Carter, April Chen, and Alita A. Miller.
Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514
ACS Infectious Diseases (2017)

Durand-Réville T, et al
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii
Nature Microbiology (2017)

Presentation Title: Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance:  ETX2514, a next-generation BLI with potent broad-spectrum activity against Class A, C and D enzymes
Presented by: Alita Miller
Meeting: 2016 Superbugs & Superdrugs USA, 2016

Presentation Title:  Global Surveillance of the Activity of Sulbactam combined with the Novel β-lactamase InhibitorETX2514 against Clinical Isolates of Acinetobacter baumannii from 2014
Presented by:  Kenneth Lawrence
Meeting:  ID Week, 2016

Presentation Title:  Human PK and Dose Projection of ETX2514 / Sulbactam Combination for Use in the Treatment of Infections Caused by Acinetobacter baumannii
Presented by:  John O’Donnell
Meeting:  ID Week, 2016

Presentation Title: Sulbactam Combined with the Novel b-lactamase Inhibitor ETX2514 for the Treatment of Multidrug-ResistantAcinetobacter baumannii Infections
Presented by:  Alita Miller
Meeting:  ID Week, 2016

Presentation Title: Addressing the Evolving Challenge of Beta-lactamase Mediated Antimicrobial Resistance: ETX2514, a Next-generation BLI with Potent, Broad Spectrum Activity Against Class A, C & D Enzymes
Presented by: Ruben Tommasi
Meeting: ASM Microbe, 2016

Poster Title: In Vitro and In Vivo Efficacy of the Novel Beta-lactamase Inhibitor ETX2514 Combined with Sulbactam Against Multidrug Resistant Acinetobacter baumannii
Presented by: John O’Donnell
Meeting: ASM Microbe, 2016

Poster Title:ETX2514, a Novel, Rationally Designed Inhibitor of Class A, C and D b-lactamases, for the Treatment of Gram-negative Infections
Presented by: Adam Shapiro
Meeting: ASM Microbe, 2016

“Our scientific approach and expertise, coupled with Entasis’ strong pipeline of programs, really make us stand out in the field of antibacterial drug discovery and development.”

— Satenig Guler, Senior Scientist